Efficacy of Ingelvac PRRS ATP demonstrated against three different challenge strains
Research conducted by veterinary researcher Pat Halbur, DVM, PhD, through Iowa State's Veterinary Diagnostic Lab demonstrates the efficacy of Ingelvac
Genetic sequencing was used to demonstrate that the three isolates varied considerably, both from each other and from the vaccine. The PRRS challenge isolates used in the study were SDSU 73, VR 2385, and Mn-01-A1 184, which were shown to be 91.7 percent, 90.1 percent, and 85.1 percent genetically similar to Ingelvac PRRS ATP vaccine, respectively. All three challenge isolates are known as highly virulent PRRS virus isolates.
A total of eight groups of 10 pigs were either vaccinated and challenged, not vaccinated and challenged, not vaccinated and not challenged, or vaccinated but not challenged. Vaccination was done at 15 days of age, and challenged pigs were exposed to one of the three PRRS challenge isolates five weeks post-vaccination. All pigs were then necropsied to check the degree of PRRS-induced pneumonia 14 days post-challenge, the presumed peak of lesion development following PRRS infection.
Pigs were also weighed on the day of vaccination, challenge, and at the termination of the study, for evaluation of average daily gain measurements. Other parameters measured in this study included: clinical signs, quantitative PCR of serum and bronchioalveolar lavage fluids for an assessment of length and amount of viremia post-challenge, and histopathological examination of lymphoid tissues, heart, and brain.
Severity of clinical signs, gross lesions, microscopic lesions, length and amount of viremia provide the data for comparison of protection between vaccinated and non-vaccinated pigs.
The results demonstrated Ingelvac PRRS ATP made a significant contribution to protecting infected pigs from lung damage as well as improving average daily gain in the presence of heterologous challenge from each of three highly virulent heterologous challenges. PRRS-induced pneumonia was significantly reduced in vaccinates as compared to non-vaccinates. Vaccinates also demonstrated a statistically significant improvement in average daily gain compared to the non-vaccinates following challenge.
Evaluation of the Efficacy of Ingelvac
To BIVI
Contact Information
Boehringer Ingelheim Vetmedica, Inc.
2621 North Belt
Highway, St. Joseph, MO 64506-2002
Phone numbers
Order Entry: 1-800-325-9167
Fax Line: 1-816-236-2717
Ingelvac is a registered trademark of Boehringer Ingelheim Vetmedica, GmbH, Ingelheim, Germany.